Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965014 | 0.86 | MAPT (0.52) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL7258139 | 0.83 | POLB (0.50) | MAPTTP53HDAC1HDAC6NOTUM | |
| Bromide SCHEMBL31588243 | 0.81 | TP53 (0.36) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL4823007 | 0.80 | ALDH1A1 (0.45) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL12649500 | 0.79 | POLB (0.52) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL3965007 | 0.79 | MAPT (0.52) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL16907793 | 0.78 | MAPT (0.69) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL7266307 | 0.77 | MAPT (0.49) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL30808595 | 0.77 | MAPT (0.65) | MAPTTP53HDAC1HDAC6NOTUM | |
| SCHEMBL21037339 | 0.74 | NOS3 (0.41) | MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002020499-A1 | PROCESS FOR THE PREPARATION OF 2-[3,4-DIHYDRO-1,4-BENZOTHIAZIN-4-YL]ETHYLMETHANE SULPHONATE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-03-14 | — | — | WO | claimed |
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | FLUORESCENCE DIAGNOSIS (SHANGHAI) BIOTECH COMPANY (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3489324-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | East China University of Science and Technology (CN) | 2019-05-29 | — | — | EP | disclosed |
| WO-2002020499-A1 | PROCESS FOR THE PREPARATION OF 2-[3,4-DIHYDRO-1,4-BENZOTHIAZIN-4-YL]ETHYLMETHANE SULPHONATE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020499-A1 | PROCESS FOR THE PREPARATION OF 2-[3,4-DIHYDRO-1,4-BENZOTHIAZIN-4-YL]ETHYLMETHANE SULPHONATE | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-03-14 | — | — | WO | disclosed |
| US-6159966-A | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them | REDDY-CHEMINOR INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0977753-A1 | AZOLIDINEDIONES USEFUL FOR THE TREATMENT OF DIABETES, DYSLIPIDEMIA AND HYPERTENSION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-02-09 | — | — | EP | disclosed |
| US-6011031-A | Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-01-04 | — | — | US | disclosed |
| WO-1998052946-A1 | AZOLIDINEDIONES USEFUL FOR THE TREATMENT OF DIABETES, DYSLIPIDEMIA AND HYPERTENSION | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190187144-A1 | FLUORESCENT PROBE AND PREPARATION METHOD AND USE THEREOF | HNRNPF, HNRNPUL2, RAB5IF | MAPT 2624/4885TP53 1649/4885HDAC1 4821/4885 |
| US-11209437-B2 | Fluorescent probe and preparation method and use thereof | HNRNPF, HNRNPUL2, RAB5IF | MAPT 2624/4885TP53 1649/4885HDAC1 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.